| 摘要 |
<p>The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to- mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.</p> |
